Stifel maintains Buy on Bicara stock with $47 target
Stifel analysts reiterated a Buy rating on Bicara Therapeutics Inc (NASDAQ:BCAX), maintaining a $47.00 price target. Trading ...
Stifel maintains Buy on MaxLinear, keeps $26 target
Stifel analysts maintained a positive outlook on MaxLinear shares (NASDAQ:MXL), reiterating a Buy rating and a price target ...